作者：孙嘉茵¹, 李宇茜¹, 熊小平¹, 樊淑宏¹, 罗婷婷¹, 雍志全², 徐小平¹

作者单位：1. 四川大学华西药学院, 四川 成都 610041;
2. 东莞达信生物技术有限公司, 广东 东莞 523808

关键词：CA4酸;抗肿瘤药;高效液相色谱;气相色谱

摘要：

对Combretastatin系列化合物的重要中间体CA4酸（CA4s）理化特征、有关物质、残留溶剂和含量测定的方法进行系统研究。通过IR、UV、MS、NMR等确定本品的化学结构。采用HPLC法检测有关物质，条件为：色谱柱C18（150 mm4.60 mm，5 m），流动相（体积比）：0.1%甲酸（氨水调解pH至6.8）-甲醇-乙腈（75：22：3），检测波长为220 nm；采用HS-GC法检测残留溶剂，条件为：PEG20M（30 m0.53 mm，1 m）的石英毛细管柱，柱温80℃，检测器温度250℃（FID），进样口温度200℃，流量4.0 mL/min，分流比：10：1；采用LC-MS鉴定本品有关物质；以剩余滴定法测定本品的含量。结果表明：CA4酸为难溶于水的浅黄色结晶性粉末，其化学结构与2-（3，4，5-三甲氧苯基）-3-[3-羟基-4-甲氧苯基]-丙烯酸相吻合，有6个杂质组分，经鉴定杂质5和杂质2为三甲氧基苯乙酸和异香草醛；杂质6为Z式CA4酸，受光照影响发生较大的变化反映出顺反异构的特征；残留溶剂乙醇量小于0.08%。CA4酸为Combretastatinl类化合物的关键中间体，难溶于水，分子中的羧基可与碱性化合物作用生成可溶性的盐，可突破该类化合物难溶性瓶颈，提高该类化合物抑制肿瘤血管的效率，是一个具有较高价值Combretastatins中间体或先导化合物。

Comprehensive study on the quality of CA4 acid as the important intermediate of tumor vascular inhibitor Combretastatins

SUN Jiayin¹, LI Yuqian¹, XIONG Xiaoping¹, FAN Shuhong¹, LUO Tingting¹, YONG Zhiquan², XU Xiaoping¹

1. West China School of Pharmacy, Sichuan University, Chengdu 610041, China;
2. Dongguan Daxin Biotechology Co., Ltd., Dongguan 523808, China

Abstract: To set up a systematic study, including the analysis on the physical and chemical features and the establishment of the methods for analysis of related substances, determination of content and the determination of residual solvent, on the CA4 acid-an important intermediates of Combretastatins, a tumor angiogenesis inhibitors-and provide the foundation for farther study on this kind of angiogenesis inhibitors. The chemical structure was confirmed by IR, UV, MS and NMR. Related substances was analyzed by HPLC and the chromatographic conditions were as follows:C18(150 mm×4.60 mm,5 μm); the mobile phase contained a mixture of 0.1% formic acid buffer(ammonia to pH 6.8), methanol and acetonitrile in a ratio of 75:22:3(v/v/v); with the wavelongth of 220 nm; The HS-GC chromatographic conditions for determination of residual solvent ethanol were as follows:analyzing in PEG capillary column(30 m×0.53 mm, 1 μm) with column temperature at 80℃, the detector temperature of FID at 250℃ and injection port temperature at 200℃, the flow rate of carrier gas nitrogen was 4.0 mL/min with diversion ratio of 10:1. Related substances were identified by LC/MS, and the content of CA4 acid was determined by the volumetric analysis. CA4 acid was light yellow amorphous powder, and was almost insoluble in water. The structure of CA4 acid is (E) -3-[(3-hydroxy-4-methoxyphenyl)]-2-(3, 4, 5-trimethoxyphenyl) acrylic acid. The fifth and second of its' six related substances were trimethoxy phenylacetic acid and isovanillin, the starting materials of CA4 acid, while the sixth was the(Z)-CA4 acid, which transformed from CA4 acid mainly because of light influences. The content of residual solvent ethanol was less than 0.08%. As the carboxyl group in the molecule can react with an alkaline compound to form a soluble salt, CA4 acid is seen as the important intermediates of Combretastatins which could enhance the efficiency of inhibiting tumor blood vessels.

Keywords: Combretastatin A4 acid;antineoplastic;HPLC;GC

2018, 44(2): 41-47  收稿日期: 2017-09-18;收到修改稿日期: 2017-10-23

基金项目: 东莞市引进创新创业领军人（201476815）

作者简介: 孙嘉茵(1991-),女,广东广州市人,硕士研究生,专业方向为药物质量控制。

参考文献

[1] PETTIT G R, CRAGG G M, HERALD D L, et al. Antineoplastic agents 84 isolation and structure of combretastatin[J]. Can J Chem,1982(60):1274-1376.
[2] KANTHOU C, GRECO O, STRATFORD A, et al. The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death[J]. Am J Pathol,2004,165(4):1401-1411.
[3] DING X, ZHANG Z, LI S, et al. Combretastatin A4 phosphate induces programmed cell death in vascular endothelial cells[J]. Oncol Res,2011,19(7):303-309.
[4] SIEMANN D W. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents[J]. Cancer Treat Rev,2011,37(1):63-74.
[5] LIN C M, HO H H, PETTIT G R, et al. Antimitotic natural products combrestastin A-4 and combretastatin A-2:studies on the mechanism of their inhibition of the binding of colchicine to tubulin[J]. Biochemistry,1989(28):6984-6991.
[6] GIAN C T, TRACEY P, GIOVANNI S, et al. Medicinal chemistry of combrestastin A-4:present and future directions[J]. JMC,2006,49(11):3033-3044.
[7] KAROL J, MACIEJ K, PRZEMYSŁAW G, et al. Combretastatins:in virto structure-activity relationship mode of action and current cliniacal status[J]. Pharmacological Reports,2016(68):1266-1275.
[8] PETTIT G R, TEMPLE C, NARAYANAN V L, et al. Antineoplastic agents 322 synthesis of combretastatin A-4 prodrugs[J]. Anti-Cancer Drug Des,1995(10):299-309.
[9] GASPARI R, PROTA A E, BARGSTEN K, et al. Structural Basis of cis-and trans-Combretastatin Binding to Tubulin[J]. Chem,2017,2(1):102-113.
[10] 韩福国,戚欣,李静. 考布他汀A4类肿瘤血管破坏剂的研究进展[J]. 中国药理学与毒理学杂志,2013,27(4):739-744.
[11] VIJAY K, PATEL H R. Significance of amino group substitution at combretastatin A-4 and phenstatin analogs[J]. Letters in Drug Design & Discovery,2016,13(9):943-951.
[12] DANA M C, DAVID J C, BRADLEY J M. The development and use of vascular targeted therapy in ovarian cancer[J]. Gynecologic Oncology,2017,145(2):393-406.
[13] EDWARD B G, JEFFREY D N, NASHAT Y G, et al.A randomized phase Ⅱ trial of the tumor vascular disrupting agent CA4P(fosbretabulin tromethamine) with carboplatin paclitaxel and bevacizumab in advanced nonsquamous non-small-cell lung cancer[J]. Onco Targets and Therapy,2016(9):7275-7283.
[14] 宁欣,陈芙蓉,张玉霞,等. 肿瘤血管抑制剂XY-02与CA4P的组织分布比较研究[J]. 中国测试,2015,41(10):53-57.
[15] 万义,赵芹,何应金,等. 大鼠口服CA4P的药物动力学研究[J]. 华西药学杂志,2010,25(1):49-51.